The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family

Current Pharmaceutical Design

Volumn 18, Issue 27, 2012, Pages 4165-4186

  Chen, Wenmin ^a   Zhan, Peng ^a   Wu, Jingde ^a   Li, Zhenyu ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

DABO; Drug design; Dual inhibitor; HEPT; HIV 1; NNRTI; Pyrimidinedione; Structure activity relationship

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; 1 (ETHOXYMETHYL) 5 ISOPROPY 6 [(3,5 DIMETHYLPHENYL)SELENENYL]URACIL; 1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE DERIVATIVE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 3 HYDROXYPYRIMIDINE 2,4 DIONE DERIVATIVE; 3 IODO 4 PHENOXYPYRIDINONE DERIVATIVE; 4 PYRIMIDINONE DERIVATIVE; 5 ETHYL 1 (INDAN 1 YLOXYMETHYL) 6 (3,5 DIMETHYLBENZYL)URACIL; 6 (3',5' DIMETHYLBENZYL) 1 ETHOXYMETHYL 5 ISOPROPYLURACIL; 6 (4 METHOXYBENZYL) 2 BUTYLOXY 3,4 DIHYDRO 4 OXOPYRIMIDINE; 6 BENZYL 1 (BENZYLOXYMETHYL) 5 ISOPROPYLPYRIMIDINE 2,4 1H,3H DIONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIHYDROALKOXYBENZYLOXOPYRIMIDINE DERIVATIVE; EFAVIRENZ; ELVITEGRAVIR; EMIVIRINE; EMIVIRINE DERIVATIVE; GCA 186; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRODRUG; R 165481; R 221239; STAVUDINE; THYMINE DERIVATIVE; TNK 651; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; LIGAND BINDING; MOLECULAR HYBRIDIZATION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; VIRUS MUTATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMINE;

EID: 84866342514     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802430440     Document Type: Review

References (139)

1. Pomerantz R, Horn D. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-873.
2. Jonckheere H, Ann J, De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 2000; 20: 129-154.
3. Campiani G, Ramunno A, Maga G, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002; 8: 615-657.
4. Boone LR. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Cur Opin Investig Drugs 2006; 7: 128-135.
5. Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602-2605.
6. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411-1413.
7. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127-1131.
8. Das K, Clark AD, Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560.
9. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-7100.
10. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
11. Miyasaka T, Tanaka H, Baba M, et al. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J Med Chem 1989; 32: 2507-2509.
12. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Nat Struct Biol 1995; 2: 303-308.
13. Tanaka H, Hayakawa H, Obi K, Tadashi M. Synthetic route to 5-substituted uridines via a new type of desulfurizative stannylation. Tetrahedron 1986; 42: 4187-4195.
14. Hayakawa H, Tanaka H, Obi K, Miyasaka T. A highly regioselective C-5 lithiation of uridine: a simple and general entry to 5-substituted uridines. Nucleic Acids Symp Ser 1986: 13-16.
15. Gaudio AC, Montanari CA. HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures. J Comput Aided Mol Des 2002; 16: 287-295.
16. Tanaka H, Takashima H, Ubasawa M, et al. Structure-activity relationships of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine analogs: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. J Med Chem 1992; 35: 337-345.
17. Tanaka H, Takashima H, Ubasawa M, et al. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem 1995; 38: 2860-2865.
18. Baba M, Shigeta S, Yuasa S, et al. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994; 38: 688-692.
19. Yuasa S, Sadakata Y, Takashima H, et al. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol Pharmacol 1993; 44: 895-900.
20. Szczech GM, Furman P, Painter GR, et al. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44: 123-130.
21. Buckheit Jr R, Hartman T, Watson K, et al. The structure-activity relationships of 2, 4 (1H, 3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir. Chem. Chemother 2007; 18: 259-275.
22. Pan B, Chen Z, Piras G, et al. Synthesis and anti-hiv-1 activities of 6-arylthio and 6-arylselenoacyclonucleosides. J Heterocycl Chem 1994; 31: 177-185.
23. Goudgaon N, Schinazi R. Activity of acyclic 6-(phenylselenenyl) pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. J Med Chem 1991; 34: 3305-3309.
24. Goudgaon N, McMillan A, Schinazi R. 1-(Ethoxymethyl)-6-(phenylselenenyl) pyrimidines with activity against human immunodeficiency virus types 1 and 2. Antivir. Chem. Chemother 1992; 3: 263-266.
25. Hopkins AL, Ren J, Tanaka H, et al. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J Med Chem 1999; 42: 4500-4505.
26. Hopkins AL, Ren J, Esnouf RM, et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors. J Med Chem 1996; 39: 1589-1600.
27. Tanaka H, Takashima H, Ubasawa M, et al. Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem 1992; 35: 4713-4719.
28. Balzarini J, Baba M, De Clercq E. Differential activities of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine derivatives against different human immunodeficiency virus type 1 mutant strains. Antimicrob Agents Chemother 1995; 39: 998.
29. Kim D, Kim Y, Gam J, et al. Synthesis and anti-HIV-1 activity of a series of 1-(alkoxymethyl)-5-alkyl-6-(arylselenenyl) uracils and-2-thiouracils. J Heterocycl Chem 1996; 33: 1275-1283.
30. Sorensen ER, El-Brollosy NR, Jorgensen PT, Pedersen EB, Nielsen C. Synthesis of 6-(3,5-dichlorobenzyl) derivatives as isosteric analogues of the HIV drug 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil (GCA-186). Arch Pharm (Weinheim) 2005; 338: 299-304.
31. El-Brollosy NR, Sorensen ER, Pedersen EB, Sanna G, La Colla P, Loddo R. Synthesis and antiviral evaluation of 6-(trifluoromethylbenzyl) and 6-(fluorobenzyl) analogues of HIV drugs emivirine and GCA-186. Arch Pharm (Weinheim) 2008; 341: 9-19.
32. Aly YL, Pedersen EB, La Colla P, Loddo R. Synthesis and anti-HIV-1 activity of new MKC-442 analogues with an alkynylsubstituted 6-benzyl group. Arch Pharm (Weinheim) 2007; 340: 225-235.
33. Sun GF, Chen XX, Chen FE, et al. Nonnucleoside HIV-1 reversetranscriptase inhibitors, part 5. Synthesis and anti-HIV-1 activity of novel 6-naphthylthio HEPT analogues. Chem Pharm Bull (Tokyo) 2005; 53: 886-892.
34. Meng G, Chen F, De Clercq E, Balzarini J, Pannecouque C. Nonnucleoside hiv-1 reverse transcriptase inhibitors: Part I. synthesis and structure-activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues. Chem Pharm Bull 2003; 51: 779-789.
35. Ji L, Chen FE, Feng XQ, De Clercq E, Balzarini J, Pannecouque C. Non-nucleoside HIV-1 reverse transcriptase inhibitors, Part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues. Chem Pharm Bull (Tokyo) 2006; 54: 1248-1253.
36. Tanaka H, Baba M, Ubasawa M, et al. Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem 1991; 34: 1394-1399.
37. Tang J, Maddali K, Dreis CD, et al. N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase. ACS Med Chem Lett 2011; 2: 63-67.
38. Tang J, Maddali K, Dreis CD, et al. 6-benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. Bioorg Med Chem Lett 2011; 21: 2400-2402.
39. Tang J, Maddali K, Sham YY, Vince R, Pommier Y, Wang Z. 3-Hydroxypyrimidine-2, 4-diones as an Inhibitor Scaffold of HIV Integrase. J Med Chem 2011; 54: 2282-2292
40. Tanaka H, Baba M, Saito S, et al. Specific anti-HIV-1 acyclonucleosides which cannot be phosphorylated: synthesis of some deoxy analogs of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine. J Med Chem 1991; 34: 1508-1511.
41. Pontikis R, Benhida R, Aubertin AM, Grierson DS, Monneret C. Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem 1997; 40: 1845-1854.
42. El-Brollosy N, Nielsen C, Pedersen E. Synthesis of N-1-(Indanyloxymethyl) and N-1-(4-hydroxybut-2-enyloxymethyl) analogues of the HIV drugs emivirine and GCA-186. Monatsh Chem 2005; 136: 1247-1254.
43. Kim D, Kim H, Lim J, et al. Synthesis and Anti-HIV-1 Activity of 1, 5-Dialkyl-6-(arylselenenyl) uracils and-2-thiouracils. J Heterocycl Chem 1996; 33: 885-894.
44. El-Brollosy N, Jorgensen P, Dahan B, Boel A, Pedersen E, Nielsen C. Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, Emivirine) with improved activity against HIV-1 and its mutants. J Med Chem 2002; 45: 5721-5726.
45. Guo HK CH.; Kim, HS.; Lee, CK.; Lee, IY.; Mitchell, ML.; Son, JC.; Xu, L.;. The novel HIV reverse transcriptase inhibitors. World Patent WO 2008016522 A2. 2008 Feb.
46. Mitchell ML, Son JC, Lee IY, et al. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2010; 20: 1585-1588.
47. Mitchell ML, Son JC, Guo H, et al. N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2010; 20: 1589-1592.
48. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001; 45: 393-400.
49. Muhsin M. Antiviral Research 14th International Conference - Overnight Report (Part IV). IDDB MEETING REPORT 2001.
50. Baba M. SJ-3366 Sam Jin Pharmaceutical. Curr Opin Investig Drugs 2002; 3: 1146-1148.
51. Ren J, Esnouf R, Garman E, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
52. Schinazi R, Larder B, Mellors J. Mutations in retroviral genes associated with drug resistance. International Antiviral News 1996; 4: 95-106.
53. Rizzo RC, Tirado-Rives J, Jorgensen WL. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. J Med Chem 2001; 44: 145-154.
54. Larder B. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994; 75: 951-957.
55. Treesuwan W, Hannongbua S. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations. J Mol Graph Model 2009; 27: 921-929.
56. Buckheit RW, Jr., Fliakas-Boltz V, Yeagy-Bargo S, et al. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 1995; 210: 186-193.
57. Hannongbua S, Nivesanond K, Lawtrakul L, Pungpo P, Wolschann P. 3D-quantitative structure-activity relationships of HEPT derivatives as HIV-1 reverse transcriptase inhibitors, based on Ab initio calculations. J Chem Inf Comput Sci 2001; 41: 848-855.
58. Kireev DB, Chretien JR, Grierson DS, Monneret C. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. J Med Chem 1997; 40: 4257-4264.
59. Luco JM, Ferretti FH. QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives. J Chem Inf Comput Sci 1997; 37: 392-401.
60. Seri-Levy A, Salter R, West S, Richards W. Shape similarity as a single independent variable in QSAR. Eur J Med Chem 1994; 29: 687-694.
61. Hansch C, Zhang L. QSAR of HIV inhibitors. Bioorg Med Chem Lett 1992; 2: 1165-1169.
62. Tanaka H, Takashima H, Ubasawa M, et al. Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. J Med Chem 1992; 35: 337-345.
63. Gayen S, Debnath B, Samanta S, Jha T. QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters. Bioorg Med Chem 2004; 12: 1493-1503.
64. Bazoui H, Zahouily M, Boulajaaj S, Sebti S, Zakarya D. QSAR for anti-HIV activity of HEPT derivatives. SAR QSAR Environ Res 2002; 13: 567-577.
65. Afantitis A, Melagraki G, Sarimveis H, Koutentis PA, Markopoulos J, Igglessi-Markopoulou O. A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis. Mol divers 2006; 10: 405-414.
66. Zarei K, Atabati M. QSAR Study of Anti-HIV Activities Against HIV-1 and Some of Their Mutant Strains for a Group of HEPT Derivatives. Journal of the Chinese Chemical Society 2009; 56: 206-213.
67. Douali L, Villemin D, Zyad A, Cherqaoui D. Artificial neural networks: non-linear QSAR studies of HEPT derivatives as HIV-1 reverse transcriptase inhibitors. Mol Divers 2004; 8: 1-8.
68. Jalali-Heravi M, Parastar F. Use of artificial neural networks in a QSAR study of anti-HIV activity for a large group of HEPT derivatives. J Chem Inf Comput Sci 2000; 40: 147-154.
69. Weekes D, Fogel GB. Evolutionary optimization, backpropagation, and data preparation issues in QSAR modeling of HIV inhibition by HEPT derivatives. Biosystems 2003; 72: 149-158.
70. Douali L, Villemin D, Cherqaoui D. Neural networks: Accurate nonlinear QSAR model for HEPT derivatives. J Chem Inf Comput Sci 2003; 43: 1200-1207.
71. Douali L, Villemin D, Cherqaoui D. Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. Curr Pharm Des 2003; 9: 1817-1826.
72. Tronchet JMJ, Grigorov M, Dolatshahi N, Moriaud F, Weber J. A QSAR study confirming the heterogeneity of the HEPT derivative series regarding their interaction with HIV reverse transcriptase. Eur J Med Chem 1997; 32: 279-299.
73. Alves C, Pinheiro J, Camargo A, Ferreira M, Da Silva A. A structure-activity relationship study of HEPT-analog compounds with anti-HIV activity. J Mol Struct: THEOCHEM 2000; 530: 39-47.
74. Tong J, Liu S. Three-Dimensional Holographic Vector of Atomic Interaction Field Applied in QSAR of Anti-HIV HEPT Analogues. QSAR Com Sci 2008; 27: 330-337.
75. Akhlaghi Y, Kompany-Zareh M. Application of radial basis function networks and successive projections algorithm in a QSAR study of anti-HIV activity for a large group of HEPT derivatives. J Chemometr 2006; 20: 1-12.
76. Darnag R, Schmitzer A, Belmiloud Y, et al. QSAR studies of HEPT derivatives using support vector machines. QSAR Com Sci 2009; 28: 709-718.
77. Lawtrakul L, Prakasvudhisarn C. Correlation studies of HEPT derivatives using swarm intelligence and support vector machines. Monatsh Chem 2005; 136: 1681-1691.
78. Lu W, Dong N, Náray-Szabó G. Predicting Anti-HIV-1 Activities of HEPT-analog Compounds by Using Support Vector Classification. QSAR Com Sci 2005; 24: 1021-1025.
79. Hannongbua S, Lawtrakul L, Sotriffer CA, Rode BM. Comparative Molecular Field Analysis of HIV-1 Reverse Transcriptase Inhibitors in the Class of 1 [(2-Hydroxyethoxy)-methyl]-6-(phenylthio) thymine. Quant Struct-Act Rel 1996; 15: 389-394.
80. Sree Latha R, Vijayaraj R, Azhagiya Singam ER, Chitra K, Subramanian V. 3D-QSAR and Docking Studies on the HEPT Derivatives of HIV-1 Reverse Transcriptase. Chem Biol Drug Des 2011; 78: 418-426.
81. Polanski J, Gieleciak R, Magdziarz T, Bak A. GRID formalism for the comparative molecular surface analysis: application to the CoMFA benchmark steroids, azo dyes, and HEPT derivatives. J Chem Inf Comput Sci 2004; 44: 1423-1435.
82. Bak A, Polanski J. A 4D-QSAR study on anti-HIV HEPT analogues. Bioorg Med Chem 2006; 14: 273-279.
83. Chiu TL, So SS. Development of neural network QSPR models for Hansch substituent constants. 2. Applications in QSAR studies of HIV-1 reverse transcriptase and dihydrofolate reductase inhibitors. J Chem Inf Comput Sci 2004; 44: 154-160.
84. Pungpo P, Punkvang A, Saparpakorn P, Wolschann P, Hannongbua S. Recent advances in NNRTI design: Computer-aided molecular design approaches. Curr Comp Aid Drug Des 2009; 5: 174-199.
85. Garg R, Gupta SP, Gao H, Babu MS, Debnath AK, Hansch C. Comparative quantitative structure-activity relationship studies on anti-HIV drugs. Chem Rev 1999; 99: 3525-3602.
86. Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet 2000; 355: 1022.
87. Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug discov today 2009; 14: 516-522.
88. Zhan P, Liu X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des 2009; 15: 1893-1917.
89. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523-6543.
90. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug discov today 2004; 9: 641-651.
91. Pontikis R, Dolle V, Guillaumel J, et al. Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase. J Med Chem 2000; 43: 1927-1939.
92. Velazquez S, Alvarez R, San-Felix A, et al. Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J Med Chem 1995; 38: 1641-1649.
93. Petersen L, Jorgensen PT, Nielsen C, Hansen TH, Nielsen J, Pedersen EB. Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach. J Med Chem 2005; 48: 1211-1220.
94. Wang Z, Bennett EM, Wilson DJ, Salomon C, Vince R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J Med Chem 2007; 50: 3416-3419.
95. Zhao G, Wang C, Liu C, Lou H. New developments in diketocontaining inhibitors of HIV-1 integrase. Mini Rev Med Chem 2007; 7: 707-725.
96. Wang Z, Vince R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg Med Chem Lett 2008; 18: 1293-1296.
97. Van Bambeke F, Michot J, Van Eldere J, Tulkens P. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-280.
98. Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro E, Fraga C. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Medicinal Chem 2007; 14: 1829-1852.
99. Goldman M, O'brien J, Ruffing T, et al. L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 1992; 36: 1019-1023.
100. Dolle V, Fan E, Nguyen C, et al. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem 1995; 38: 4679-4686.
101. Dolle V, Nguyen C, Legraverend M, et al. Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. J Med Chem 2000; 43: 3949-3962.
102. Benjahad A, Guillemont J, Andries K, Nguyen CH, Grierson DS. 3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2003; 13: 4309-4312.
103. Benjahad A, Courte K, Guillemont J, et al. 4-benzyl-and 4-benzoyl-3-dimethylaminopyridin-2 (1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains. J Med Chem 2004; 47: 5501-5514.
104. Le Van K, Cauvin C, de Walque S, et al. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. J Med Chem 2009; 52: 3636-3643.
105. Benjahad A, Croisy M, Monneret C, et al. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2 (1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5, 6-alkyl-substituted analogues against clinically important HIV mutant strains. J Med Chem 2005; 48: 1948-1964.
106. Himmel DM, Das K, Clark AD, Jr., et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem 2005; 48: 7582-7591.
107. Guillemont J, Benjahad A, Oumouch S, et al. Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. J Med Chem 2009; 52: 7473-7487.
108. Botta M, Artico M, Massa S, et al. Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives. Eur J Med Chem 1992; 27: 251-257.
109. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exp Opin Invest Drugs 1994; 3: 253-271.
110. Tramontano E, Marongiu M, De Montis A, et al. Characterization of the anti-HIV-1 activity of 3, 4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors. The new microbiologica: official journal of the Italian Society for Medical, Odontoiatric, and Clinical Microbiology (SIMMOC) 1994; 17: 269-279.
111. Artico M, Massa S, Mai A, et al. 3, 4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antivir Chem Chemother 1993; 4: 361-368.
112. Massa S, Mai A, Artico M, et al. Synthesis and antiviral activity of new 3, 4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antivir Chem Chemother 1995; 6: 1-8.
113. Mai A, Artico M, Sbardella G, et al. Dihydro (alkylthio)(naphthylmethyl) oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J Med Chem 1997; 40: 1447-1454.
114. He YP, Long J, Zhang SS, et al. Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyloxopyrimidines (S-DACOs) as high active anti-HIV agents. Bioorg Med Chem Lett 2011; 21: 694-697.
115. Sbardella G, Mai A, Artico M, et al. Structure-activity relationship studies on new DABOS: effect of substitutions at pyimidinedione C-5 and C-6 positions on anti-HIV-1 activity. Antivir Chem Chemother 2001; 12: 37-50.
116. Mai A, Artico M, Sbardella G, et al. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J Med Chem 1999; 42: 619-627.
117. Sbardella GM, Artico A, Massa M, et al. Does the 2-Methylthiomethyl Substituent Really Confer High Anti-HIV-1 Activity to S-DABOs. Med. Chem. Res. 2000; 10-39.
118. Quaglia M, Mai A, Sbardella G, et al. Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2, 6-difluorophenyl) ethyl]-3, 4-dihydro-5-methylpyrimidin-4 (3H)- one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. Chirality 2001; 13: 75-80.
119. Mai A, Sbardella G, Artico M, et al. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4 (3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2001; 44: 2544-2554.
120. Ragno R, Mai A, Sbardella G, et al. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2, 6-difluorophenyl) alkyl]-3, 4-dihydro-5-alkylpyrimidin-4 (3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem 2004; 47: 928-934.
121. Mai A, Artico M, Rotili D, et al. Synthesis and biological properties of novel 2-Aminopyrimidin-4 (3H)-ones highly potent against HIV-1 mutant strains. J Med Chem 2007; 50: 5412-5424.
122. Nawrozkij M, Rotili D, Tarantino D, et al. 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl) pyrimidin-4 (3H)-ones, a Series of antihiv-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure- activity relationship profile. J Med Chem 2008; 51: 4641-4652.
123. Manetti F, Este J, Clotet-Codina I, et al. Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity. J Med Chem 2005; 48: 8000-8008.
124. Mugnaini C, Alongi M, Togninelli A, et al. Dihydro-alkylthiobenzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wildtype enzyme and relevant clinical mutants. J Med Chem 2007; 50: 6580-6595.
125. Wang Y, Chen F, De Clercq E, Balzarini J, Pannecouque C. Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio) pyrimidin-4 (3H)-ones as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2008; 16: 3887-3894.
126. He Y, Chen F, Sun G, et al. 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl) thio]-6-(1-naphthylmethyl) pyrimidin-4 (3H)-ones as an unique HIV reverse transcriptase inhibitors of SDABO series. Bioorg Med Chem Lett 2004; 14: 3173-3176.
127. Yu M, Liu X, Li Z, Liu S, Pannecouque C, Clercq E. Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2, 6-dichlorobenzyl)-pyrimidin-4 (3H)-ones as potent HIV-1 NNRTIs. Bioorg Med Chem Lett 2009; 17: 7749-7754.
128. Hsiou Y, Das K, Ding J, et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998; 284: 313-323.
129. Das K, Ding J, Hsiou Y, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 1996; 264: 1085-1100.
130. Das K, Sarafianos SG, Clark AD, Jr., Boyer PL, Hughes SH, Arnold E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol 2007; 365: 77-89.
131. Ren J, Nichols CE, Chamberlain PP, et al. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J Med Chem 2007; 50: 2301-2309.
132. Hauser A, Mugenyi K, Kabasinguzi R, et al. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother 2009; 53: 2965-2973.
133. Magiorkinis E, Paraskevis D, Sambatakou H, et al. Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTInaive patient. AIDS Res Hum Retroviruses 2008; 24: 413-415.
134. Saen-oon S, Kuno M, Hannongbua S. Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method. Proteins 2005; 61: 859-869.
135. Polilli E, Parruti G, Cosentino L, et al. Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. J Med Case Reports 2009; 3: 9132-9147.
136. El-Brollosy NR, Jorgensen PT, Dahan B, Boel AM, Pedersen EB, Nielsen C. Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. J Med Chem 2002; 45: 5721-5726.
137. Janssen P, Lewi P, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl] amino]-2-pyrimidinyl] amino] benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48: 1901-1909.
138. Ren J, Stammers D. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 2008; 134: 157-170.
139. Zhan P, Liu X, Li Z, Pannecouque C, De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009; 16: 3903-3917.